The National Institute for Health and Care Excellence (NICE) has rejected the routine use of Biogen Idec’s oral multiple sclerosis (MS) treatment Tecfidera in draft guidance. NICE, which assesses the value of drugs for use on the NHS in England and Wales, said that Tecfidera (dimethyl fumarate) was not a cost-effective use of NHS resources to treat adults with relapsing-remitting MS; when used as recommended a year’s treatment costs more than £16,000.
Help employers find you! Check out all the jobs and post your resume.
